Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
A 75-year-old man with metastatic prostate cancer had been treated with goserelin acetate, and prostate specific antigen (PSA) had decreased, but 11/2 years after beginning the treatment of goserelin acetate, PSA was markedly elevated and serum testosterone was at normal level. After castration the serum testosterone was at castrate level and PSA decreased. In the present case, leuprorelin acetate 1-month depot suppressed the luteinizing hormone level in 1 month, even after the patient underwent castration.
Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Nakamichi, Higashinari-ku, Japan. t-kinouchi@sannet.ne.jp
Toshiaki
T
Kinouchi
Osamu
O
Maeda
Yutaka
Y
Ono
Norio
N
Meguro
Masao
M
Kuroda
Michiyuki
M
Usami
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D000368:Aged; D005300:Fertility Agents, Female / Q000819:agonists* / Q000627:therapeutic use*; D012739:Gonadal Steroid Hormones / Q000037:antagonists & inhibitors* / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D013739:Testosterone / Q000037:antagonists & inhibitors* / Q000097:blood*; D017211:Treatment Failure
D005300:Fertility Agents, Female; D012739:Gonadal Steroid Hormones; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone